22nd Jan 2024 The DESTINY-Breast03 study: a plain language summary comparing trastuzumab deruxtecan with trastuzumab emtansine for breast cancer
3rd Nov 2023 A plain language summary of the DESTINY-Gastric01 study: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
6th Oct 2023 The TOPAZ-1 study: a plain language summary describing durvalumab and chemotherapy for advanced biliary tract cancer
11th Apr 2023 Plain Language Summary: the CheckMate 649 study compares nivolumab in combination with chemotherapy with chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus